These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 37699890)

  • 41. Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents.
    Zheng Y; Pan J; Jin M; Wang J; Tung TH; Chen S; Bi X; Zhou K; Chen M; Wang D; Li J; Shen B; Ying L
    Int Immunopharmacol; 2023 Jun; 119():110151. PubMed ID: 37044040
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunological imprinting of humoral immunity to SARS-CoV-2 in children.
    Dowell AC; Lancaster T; Bruton R; Ireland G; Bentley C; Sylla P; Zuo J; Scott S; Jadir A; Begum J; Roberts T; Stephens C; Ditta S; Shepherdson R; Powell AA; Brent AJ; Brent B; Baawuah F; Okike I; Beckmann J; Ahmad S; Aiano F; Garstang J; Ramsay ME; Azad R; Waiblinger D; Willett B; Wright J; Ladhani SN; Moss P
    Nat Commun; 2023 Jun; 14(1):3845. PubMed ID: 37386081
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of Long-Term Adaptive Immune Responses Specific to SARS-CoV-2: Effect of Various Vaccination and Omicron Exposure.
    Kang H; Jung J; Ko GY; Lee J; Oh EJ
    Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543935
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.
    Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Couto CIC; Güler A; Mampilli V; Schmitt GJ; Mottl J; Ziegenhals T; Fesser S; Reinholz J; Wernig F; Schraut KG; Hefesha H; Cai H; Yang Q; Walzer KC; Grosser J; Strauss S; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Kohmer N; Ciesek S; Swanson KA; Vogel AB; Türeci Ö; Sahin U
    Sci Immunol; 2022 Dec; 7(78):eade9888. PubMed ID: 36378074
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects.
    Haveri A; Solastie A; Ekström N; Österlund P; Nohynek H; Nieminen T; Palmu AA; Melin M
    Eur J Immunol; 2022 May; 52(5):816-824. PubMed ID: 35312186
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine.
    Azzi L; Dalla Gasperina D; Veronesi G; Shallak M; Maurino V; Baj A; Gianfagna F; Cavallo P; Dentali F; Tettamanti L; Maggi F; Maffioli LS; Tagliabue A; Accolla RS; Forlani G
    EBioMedicine; 2023 Feb; 88():104435. PubMed ID: 36628844
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
    Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
    Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study.
    Zhang Y; Qu JW; Zheng MN; Ding YX; Chen W; Ye SD; Li XY; Li YK; Liu Y; Zhu D; Jin CR; Wang L; Yang JY; Zhai Y; Wang EQ; Meng X
    Biomed Environ Sci; 2023 Jul; 36(7):614-624. PubMed ID: 37533385
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort.
    Lavender B; Hooker C; Frampton C; Williams M; Carson S; Paterson A; McGregor R; Moreland NJ; Gell K; Priddy FH; Wiig K; Le Gros G; Ussher JE; Brewerton M
    Vaccine; 2023 Aug; 41(38):5535-5544. PubMed ID: 37516574
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ad5-nCoV booster and Omicron variant breakthrough infection following two doses of inactivated vaccine elicit comparable antibody levels against Omicron variants.
    Kong W; Zhong Q; Chen M; Yu P; Xu R; Zhang L; Lai C; Deng M; Zhou Q; Xiong S; Liang Y; Wan L; Lin M; Wang M; Mai W; Chen L; Lei Y; Qin N; Zhu J; Ruan J; Huang Q; Kang A; Wang J; Li W; Ji T
    J Med Virol; 2023 Jan; 95(1):e28163. PubMed ID: 36127294
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mucosal and Systemic Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Determined by Severity of Primary Infection.
    Sajadi MM; Myers A; Logue J; Saadat S; Shokatpour N; Quinn J; Newman M; Deming M; Rikhtegaran Tehrani Z; Magder LS; Karimi M; Abbasi A; Shlyak M; Baracco L; Frieman MB; Crotty S; Harris AD
    mSphere; 2022 Dec; 7(6):e0027922. PubMed ID: 36321826
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SARS-CoV-2 immune response and reinfection in vaccinated Maya and mestizo in Southeast of Mexico.
    Monteón V; León-Pérez F; Ancona-León JG; Gutiérrez-Torres G
    Salud Publica Mex; 2023 Dec; 66(1, ene-feb):14-16. PubMed ID: 38065105
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictors of reinfection with pre-Omicron and Omicron variants of concern among individuals who recovered from COVID-19 in the first year of the pandemic.
    Cohen D; Izak M; Stoyanov E; Mandelboim M; Perlman S; Amir Y; Goren S; Bialik A; Kliker L; Atari N; Yshai R; Zaide Y; Marcus H; Madar-Balakirski N; Israely T; Paran N; Zimhony O; Shinar E; Maor Y; Muhsen K
    Int J Infect Dis; 2023 Jul; 132():72-79. PubMed ID: 37072052
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern.
    McNamara RP; Maron JS; Boucau J; Roy V; Webb NE; Bertera HL; Barczak AK; Positives Study Staff T; Franko N; Logue JK; Kemp M; Li JZ; Zhou L; Hsieh CL; McLellan JS; Siedner MJ; Seaman MS; Lemieux JE; Chu HY; Alter G
    mBio; 2023 Aug; 14(4):e0090223. PubMed ID: 37535402
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pediatric humoral immune responses and infection risk after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and two-dose vaccination during SARS-CoV-2 omicron BA.5 and BN.1 variants predominance in South Korea.
    Choi HW; Achangwa C; Park J; Lee SM; Lee NY; Jeon CH; Choi JH; Do HK; Nam JH; Lee JW; Kim B; Ryu S; Kee SJ
    Front Immunol; 2023; 14():1306604. PubMed ID: 38193075
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of Neutralizing Activity against Omicron Subvariants in BA.5 Breakthrough Infection and Three-Dose Vaccination Using a Novel Chemiluminescence-Based, Virus-Mediated Cytopathic Assay.
    Toyoda M; Tan TS; Motozono C; Barabona G; Yonekawa A; Shimono N; Minami R; Nagasaki Y; Miyashita Y; Oshiumi H; Nakamura K; Matsushita S; Kuwata T; Ueno T
    Microbiol Spectr; 2023 Aug; 11(4):e0066023. PubMed ID: 37310218
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
    Tan NH; Geers D; Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Bogers S; van Dijk LLA; Gommers L; van Leeuwen LPM; Boerma A; Nijhof SH; van Dort KA; Koopmans MPG; Dalm VASH; Lafeber M; Kootstra NA; Huckriede ALW; van Baarle D; Zaeck LM; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
    Lancet Infect Dis; 2023 Aug; 23(8):901-913. PubMed ID: 37088096
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals.
    Kuzel TG; Fu J; Anderson M; Stec M; Boler M; Behun D; Gosha A; Cloherty G; Landay A; Moy J
    Vaccine; 2023 Jan; 41(4):879-882. PubMed ID: 36572601
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BNT162b2 vaccine induced variant-specific immunity, safety and risk of Omicron breakthrough infection in children aged 5 to 11 years: a cohort study.
    Yung CF; Le Bert N; Kam KQ; Saffari SE; Tan CW; Mah YY; Zhang J; Yeoh AY; Zhu F; Hariharaputran S; Chong CY; Bertoletti A; Wang L
    Sci Rep; 2023 Oct; 13(1):17337. PubMed ID: 37833554
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico.
    Montes-González JA; Zaragoza-Jiménez CA; Antonio-Villa NE; Fermín-Martínez CA; Ramírez-García D; Vargas-Vázquez A; Gutiérrez-Vargas RI; García-Rodríguez G; López-Gatell H; Valdés-Ferrer SI; Bello-Chavolla OY
    Front Public Health; 2023; 11():1146059. PubMed ID: 37081954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.